• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Developmental and Physical Disabilities >Secretin in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled Trial
【24h】

Secretin in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled Trial

机译：自闭症患儿的促胰液素：一项双盲，安慰剂对照的试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A number of recent studies have examined the efficacy of secretin (a polypeptide neurotransmitter) to treat symptoms associated with autism. Initial anecdotal reports indicated significant gains in social relatedness and language. However, recent double-blind studies have documented few significant differences between placebo and active medication. We report the results of a double-blind, placebo-controlled, crossover study of the efficacy of secretin in eight children with autism. No group differences between placebo and secretin were found on measures of behavior and core features of autism. Parents reported anecdotal improvement in communication and social relatedness, but such gains tended to occur during both placebo and active medication conditions. However, a single subject did experience improvement in the core features of autism and behavior for a 3–4-week period following the secretin infusion. The results add further research support of the lack of clinical efficacy of this medication in the treatment of autism.
机译：最近的许多研究已经检查了促胰液素（一种多肽神经递质）治疗自闭症相关症状的功效。最初的传闻报道表明，在社交和语言方面取得了重大进展。但是，最近的双盲研究表明，安慰剂和活性药物之间几乎没有显着差异。我们报告了八名自闭症儿童促胰液素功效的双盲，安慰剂对照，交叉研究的结果。在行为和自闭症核心特征的测量上未发现安慰剂和促胰液素之间的群体差异。父母报告说交流和社交相关性得到了改善，但是在安慰剂和积极用药期间，这种收获往往会发生。但是，在注射促胰液素后的3到4周内，单个受试者的自闭症和行为的核心特征确实有所改善。结果为该药物缺乏治疗自闭症的临床疗效提供了进一步的研究支持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号